Th17 Cells as Potential Probiotic Therapeutic Targets in Inflammatory Bowel Diseases - PubMed (original) (raw)

Review

Th17 Cells as Potential Probiotic Therapeutic Targets in Inflammatory Bowel Diseases

Eddy Owaga et al. Int J Mol Sci. 2015.

Abstract

Inflammatory bowel diseases (IBD) are characterized by wasting and chronic intestinal inflammation triggered by various cytokine-mediated pathways. In recent years, it was shown that T helper 17 (Th17) cells are involved in the pathogenesis of IBD, which makes them an attractive therapeutic target. Th17 cells preferentially produce interleukin (IL)-17A-F as signature cytokines. The role of the interplay between host genetics and intestinal microbiota in the pathogenesis of IBD was demonstrated. Probiotics are live microorganisms that when orally ingested in adequate amounts, confer a health benefit to the host by modulating the enteric flora or by stimulating the local immune system. Several studies indicated the effectiveness of probiotics in preventing and treating IBD (ulcerative colitis, and Crohn's disease). Furthermore, there is mounting evidence of probiotics selectively targeting the Th17 lineage in the prevention and management of inflammatory and autoimmune diseases such as IBD. This review highlights critical roles of Th17 cells in the pathogenesis of IBD and the rationale for using probiotics as a novel therapeutic approach for IBD through manipulation of Th17 cells. The potential molecular mechanisms by which probiotics modulate Th17 cells differentiation and production are also discussed.

Keywords: IL-17; Th17; inflammation; inflammatory bowel diseases; probiotics.

PubMed Disclaimer

Similar articles

• Contribution of the IL-17/IL-23 axis to the pathogenesis of inflammatory bowel disease.
  Cătană CS, Berindan Neagoe I, Cozma V, Magdaş C, Tăbăran F, Dumitraşcu DL. Cătană CS, et al. World J Gastroenterol. 2015 May 21;21(19):5823-30. doi: 10.3748/wjg.v21.i19.5823. World J Gastroenterol. 2015. PMID: 26019446 Free PMC article. Review.
• The effect of probiotics and gut microbiota on Th17 cells.
  Tanabe S. Tanabe S. Int Rev Immunol. 2013 Oct-Dec;32(5-6):511-25. doi: 10.3109/08830185.2013.839665. Epub 2013 Oct 4. Int Rev Immunol. 2013. PMID: 24094077 Review.
• Th17 cytokines in inflammatory bowel diseases: discerning the good from the bad.
  Troncone E, Marafini I, Pallone F, Monteleone G. Troncone E, et al. Int Rev Immunol. 2013 Oct-Dec;32(5-6):526-33. doi: 10.3109/08830185.2013.823421. Epub 2013 Sep 16. Int Rev Immunol. 2013. PMID: 24041379 Review.
• The Th17 cell population and the immune homeostasis of the gastrointestinal tract.
  Rossi M, Bot A. Rossi M, et al. Int Rev Immunol. 2013 Oct-Dec;32(5-6):471-4. doi: 10.3109/08830185.2013.843983. Int Rev Immunol. 2013. PMID: 24164337
• The Function and Role of the Th17/Treg Cell Balance in Inflammatory Bowel Disease.
  Yan JB, Luo MM, Chen ZY, He BH. Yan JB, et al. J Immunol Res. 2020 Dec 15;2020:8813558. doi: 10.1155/2020/8813558. eCollection 2020. J Immunol Res. 2020. PMID: 33381606 Free PMC article. Review.

Cited by

• Eosinophils in Autoimmune Diseases.
  Diny NL, Rose NR, Čiháková D. Diny NL, et al. Front Immunol. 2017 Apr 27;8:484. doi: 10.3389/fimmu.2017.00484. eCollection 2017. Front Immunol. 2017. PMID: 28496445 Free PMC article. Review.
• Macrophage Subset Expressing CD169 in Peritoneal Cavity-Regulated Mucosal Inflammation Together with Lower Levels of CCL22.
  Wang D, Li Q, Yang Y, Hao S, Han X, Song J, Yin Y, Li X, Tanaka M, Qiu CH. Wang D, et al. Inflammation. 2017 Aug;40(4):1191-1203. doi: 10.1007/s10753-017-0562-0. Inflammation. 2017. PMID: 28466432
• Human gut microbiota in health and disease: Unveiling the relationship.
  Afzaal M, Saeed F, Shah YA, Hussain M, Rabail R, Socol CT, Hassoun A, Pateiro M, Lorenzo JM, Rusu AV, Aadil RM. Afzaal M, et al. Front Microbiol. 2022 Sep 26;13:999001. doi: 10.3389/fmicb.2022.999001. eCollection 2022. Front Microbiol. 2022. PMID: 36225386 Free PMC article. Review.
• Effect of a seven-strain probiotic on dietary intake, inflammatory markers, and T-cells in severe traumatic brain injury patients: A randomized, double-blind, placebo-controlled trial.
  Abbaszadeh SH, Yousefi M, Arefhosseini SR, Mahmoodpoor A, Mameghani ME. Abbaszadeh SH, et al. Sci Prog. 2024 Jul-Sep;107(3):368504241259299. doi: 10.1177/00368504241259299. Sci Prog. 2024. PMID: 39196597 Free PMC article. Clinical Trial.
• Probiotics in Treatment of Viral Respiratory Infections and Neuroinflammatory Disorders.
  Shahbazi R, Yasavoli-Sharahi H, Alsadi N, Ismail N, Matar C. Shahbazi R, et al. Molecules. 2020 Oct 22;25(21):4891. doi: 10.3390/molecules25214891. Molecules. 2020. PMID: 33105830 Free PMC article. Review.

References

1. 1. Dai C., Zheng C.-Q., Jiang M., Ma X.Y., Jiang L.J. Probiotics and irritable bowel syndrome. World J. Gastroenterol. 2013;19:5973–5980. doi: 10.3748/wjg.v19.i36.5973. - DOI - PMC - PubMed
2. 1. Khor B., Gardet A., Xavier R.J. Genetics and pathogenesis of inflammatory bowel disease. Nature. 2011;474:307–317. doi: 10.1038/nature10209. - DOI - PMC - PubMed
3. 1. Sheil B., Shanahan F., O’Mahony L. Probiotic effects on inflammatory bowel disease. J. Nutr. 2007;137:819S–824S. - PubMed
4. 1. Gálvez J. Role of Th17 cells in the pathogenesis of human IBD. ISRN Inflamm. 2014;2014:928461. doi: 10.1155/2014/928461. - DOI - PMC - PubMed
5. 1. Liu Z.-J., Yadav P.K., Su J.-L., Wang J.S., Fei K. Potential role of Th17 cells in the pathogenesis of inflammatory bowel disease. J. Gastroenterol. 2009;15:5784–5788. doi: 10.3748/wjg.15.5784. - DOI - PMC - PubMed

Publication types

MeSH terms

LinkOut - more resources

• Full Text Sources

  • Europe PubMed Central
  • MDPI
  • PubMed Central

• Other Literature Sources

  • The Lens - Patent Citations Database
  • scite Smart Citations